SRPT
USDSarepta Therapeutics Inc. Common Stock (DE)
Precio en Tiempo Real
Gráfico de Precios
Métricas Clave
Métricas de Mercado
Apertura
$15.310
Máximo
$17.750
Mínimo
$15.080
Volumen
2.09M
Fundamentos de la Empresa
Capitalización de Mercado
1.7B
Industria
Biotecnología
País
United States
Estadísticas de Negociación
Volumen Promedio
7.10M
Bolsa
NMS
Moneda
USD
Rango de 52 Semanas
Noticias Relacionadas
Sarepta Faces Investor Skepticism As Duchenne Data Falls Short Of Statistical Significance
Sarepta's Duchenne trial missed its main goal but showed trends favoring treatment; Q3 earnings topped estimates amid Elevidys sales weakness.
Baird Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $15
Baird analyst Brian Skorney maintains Sarepta Therapeutics with a Neutral and lowers the price target from $21 to $15.
Futures tumble after Wall St banks warn of market pullback, Palantir slides
U.S. stock futures tumbled on Tuesday as investors questioned lofty valuations in the technology sector after top Wall Street banks warned of a stock market selloff and AI darling Palantir's sales forecast failed to lift the mood.
Sarepta slumps as gene therapy setback adds to drug pipeline woes
Shares of Sarepta sank 36% before the bell on Tuesday after a trial for two gene-targeted therapies for a muscle-wasting disease missed a key goal, deepening concerns about the company's treatment pipeline.
Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE
Sarepta announces completion of the confirmatory trial commitment for its ultra-rare disease PMO therapies AMONDYS 45 and VYONDYS 53: While the ESSENCE study did not achieve statistical significance on its primary
Piper Sandler Maintains Neutral on Sarepta Therapeutics, Raises Price Target to $16
Piper Sandler analyst Biren Amin maintains Sarepta Therapeutics with a Neutral and raises the price target from $15 to $16.
Sarepta Therapeutics to Announce Third Quarter 2025 Financial Results
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2025 financial results after the Nasdaq Global Market closes on Monday, Nov. 3, 2025.
Acciones Relacionadas
VOC
VOC Energy Trust Units of Beneficial Interest
FMN
Federated Hermes Premier Municipal Income Fund
SNCRL
Synchronoss Technologies Inc. 8.375% Senior Notes due 2026
FTHM
Fathom Holdings Inc.
PBI
Pitney Bowes Inc.
Mantente Actualizado
Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.